Astrazeneca Pharma India Results: Latest Quarterly Results & Analysis

Pharmaceuticals company AstraZeneca Pharma India announced Q2FY25 results

• Revenue from Operations: Rs 3,875.2 milllion compared to Rs 4,080.0 milllion during Q2FY24.
• PBT: Rs 424.0 milllion compared to Rs 510.3 milllion during Q2FY24.
• PAT: Rs -117.9 milllion compared to Rs 384.3 milllion during Q2FY24.

Bhavana Agrawal, Chief Financial Officer AstraZeneca Pharma India, said: “We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31% bringing our H1 revenue from operations to Rs 7,955.2 milllion, driven by our portfolio -Oncology, Biopharmaceuticals and Rare Disease. The growth of the company is a derivative of our ambition to bring innovative medicines faster in the country for unmet patient needs”.

Sanjeev Panchal, Country President & Managing Director, AstraZeneca Pharma India, said: “We are transforming the future of healthcare by unlocking the power of what science can do, for people, society, and planet. With a Growth Through Innovation strategy, we are constantly working towards expanding access to innovative therapies, progressive access strategies, and making healthcare systems resilient in India”.

Result PDF

Pharmaceuticals company AstraZeneca Pharma India announced Q1FY25 results: 

• Revenue from Operation for the quarter stood at Rs 3,875.2 million with substantial 31% increase demonstrating Company’s focus on improving access to patients.
• Profit before exceptional item and tax is Rs 424 million (11% of the total Income ) reflecting the Company’s efforts on driving profitable growth.
• Loss after exceptional item and tax  is Rs 117.9 million ( -3% of total income ) due to booking of provisions associated with exit of factory site announced in this quarter.

Sanjeev Panchal, Country President and Managing Director, AstraZeneca India, commented, " We are pleased to report a strong financial performance this quarter. It reflects our continuous endeavour of harnessing science and commitment to bringing innovative medicines faster to India. We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programs focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers, and non-government organizations."

Bhavana Agrawal, Chief Finance Officer, added, "It’s a strong start of the year with 31% revenue growth and double-digit profit margin (before exceptional item and tax). The results are an outcome of Company’s focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years. We are continuously pushing the boundaries of science and are well positioned for consistent value creation for our customers and shareholders.”

Result PDF

Pharmaceuticals company AstraZeneca Pharma India announced FY24 results:

• Revenue from Operations for FY24 stood at Rs 1,296 crore with substantial 29% increase.
• Profit Before Tax is Rs 220 crore registering a commendable 64% growth (PBT before exceptional items at Rs 201 crore, up by 17% compared to previous financial year).
• Earnings Per Share (EPS) for financial year stood at Rs 64.6 demonstrating a significant growth of 63%
• The Board of Directors, at its meeting dated May 27, 2024, have recommended a final dividend of Rs. 24 per equity share for FY24, subject to approval of shareholders at the Annual General Meeting of the Company.

Sanjeev Panchal, Country President and Managing Director, AstraZeneca India, commented, " FY24 was one of the strongest years for us in the country and we take immense pride in our consistent performance. AstraZeneca India products sales for first  time cross Rs 1000 crore mark, delivering total revenue of almost Rs ~1300 crore with growth of 29% this year. A successful execution of our growth through innovation strategy is helping us propel our ambition to be pioneers in science and lead in specialist disease areasin India. Science is guiding us, and our remarkable pipeline progress with 9 new medicines and indication approvals that we received last year, positions us optimally and we feel motivated to bring more innovative therapies faster and closer to patients in India.

Our scientific progress and great support from different states, peers, and industry stakeholders positions us optimally to achieve our purpose of leaving no patients behind in the therapy areas we are present in and sustainably continue our strive to contribute to people, society, and the planet."

Bhavana Agrawal, Chief Finance Officer, added, "Our strong full year performance is reflection of company’s focus on being a specialist organization & strong operational execution. This achievement reflects our relentless pursuit of identifying and capitalizing on opportunities in a dynamic environment. It underscores our dedication to not only achieving financial excellence but doing so in a sustainable and strategic manner."

Result PDF